![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/07/01/2906564/0/en/Improvement-in-Patient-with-Decompensated-Liver-Cirrhosis-Upon-Treatment-with-Namodenoson.html
https://www.businesswire.com/news/home/20200715005283/en/Can-Fite-Completes-Phase-II-COVID-19-Protocol-Based
https://www.biospace.com/article/releases/can-fite-updates-on-clinical-milestone-for-its-phase-iii-rheumatoid-arthritis-study-with-piclidenoson-drugs-combating-rheumatoid-arthritis-are-currently-introduced-for-the-treatment-of-the-coronavirus/
https://markets.businessinsider.com/news/stocks/can-fite-completes-50-patient-enrollment-in-phase-iii-rheumatoid-arthritis-study-implements-interim-analysis-1028867348
https://www.businesswire.com/news/home/20180702005387/en/Drugs-Mechanism-Action-Utilized-Namodenoson-Recommended-Leading